Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10617128rdf:typepubmed:Citationlld:pubmed
pubmed-article:10617128lifeskim:mentionsumls-concept:C0001554lld:lifeskim
pubmed-article:10617128lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:10617128lifeskim:mentionsumls-concept:C0521119lld:lifeskim
pubmed-article:10617128lifeskim:mentionsumls-concept:C0013030lld:lifeskim
pubmed-article:10617128lifeskim:mentionsumls-concept:C0035179lld:lifeskim
pubmed-article:10617128lifeskim:mentionsumls-concept:C0011307lld:lifeskim
pubmed-article:10617128lifeskim:mentionsumls-concept:C0442805lld:lifeskim
pubmed-article:10617128lifeskim:mentionsumls-concept:C1550147lld:lifeskim
pubmed-article:10617128lifeskim:mentionsumls-concept:C1292733lld:lifeskim
pubmed-article:10617128pubmed:issue1lld:pubmed
pubmed-article:10617128pubmed:dateCreated2000-1-18lld:pubmed
pubmed-article:10617128pubmed:abstractTextThe influence of L-DOPA and reserpine on extracellular dopamine (DA) levels in the striatum of intact and dopaminergic denervated rats was studied using the brain microdialysis technique. In intact rats, reserpine (5 mg/kg s.c.) reduced extracellular DA levels to 4% of basal values. L-DOPA (50 mg/kg i.p.) had no effect on extracellular DA levels in reserpine-pretreated rats. In rats with 6-hydroxydopamine-induced lesion of the nigrostriatal dopaminergic system, basal levels of extracellular DA were low but markedly increased by L-DOPA (50 mg/kg i.p.). In 6-hydroxydopamine-lesioned rats, pretreatment with reserpine (5 mg/kg s.c.) diminished L-DOPA (50 mg/kg i.p.)-induced increases in extracellular DA levels to 16% of those obtained in denervated animals not pretreated with reserpine (p<0.01). These results suggest that in the intact striatum, extracellular DA stems mainly from vesicular storage sites and that in the striatum with dopaminergic denervation, a large part of the L-DOPA-derived extracellular DA is also derived from a vesicular pool that is released by an exocytosis mechanism.lld:pubmed
pubmed-article:10617128pubmed:languageenglld:pubmed
pubmed-article:10617128pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10617128pubmed:citationSubsetIMlld:pubmed
pubmed-article:10617128pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10617128pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10617128pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10617128pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10617128pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10617128pubmed:statusMEDLINElld:pubmed
pubmed-article:10617128pubmed:monthJanlld:pubmed
pubmed-article:10617128pubmed:issn0022-3042lld:pubmed
pubmed-article:10617128pubmed:authorpubmed-author:TanakaHHlld:pubmed
pubmed-article:10617128pubmed:authorpubmed-author:MaedaTTlld:pubmed
pubmed-article:10617128pubmed:authorpubmed-author:MatsunagaMMlld:pubmed
pubmed-article:10617128pubmed:authorpubmed-author:SudaTTlld:pubmed
pubmed-article:10617128pubmed:authorpubmed-author:TomiyamaMMlld:pubmed
pubmed-article:10617128pubmed:authorpubmed-author:KannariKKlld:pubmed
pubmed-article:10617128pubmed:issnTypePrintlld:pubmed
pubmed-article:10617128pubmed:volume74lld:pubmed
pubmed-article:10617128pubmed:ownerNLMlld:pubmed
pubmed-article:10617128pubmed:authorsCompleteYlld:pubmed
pubmed-article:10617128pubmed:pagination263-9lld:pubmed
pubmed-article:10617128pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:10617128pubmed:meshHeadingpubmed-meshheading:10617128...lld:pubmed
pubmed-article:10617128pubmed:meshHeadingpubmed-meshheading:10617128...lld:pubmed
pubmed-article:10617128pubmed:meshHeadingpubmed-meshheading:10617128...lld:pubmed
pubmed-article:10617128pubmed:meshHeadingpubmed-meshheading:10617128...lld:pubmed
pubmed-article:10617128pubmed:meshHeadingpubmed-meshheading:10617128...lld:pubmed
pubmed-article:10617128pubmed:meshHeadingpubmed-meshheading:10617128...lld:pubmed
pubmed-article:10617128pubmed:meshHeadingpubmed-meshheading:10617128...lld:pubmed
pubmed-article:10617128pubmed:meshHeadingpubmed-meshheading:10617128...lld:pubmed
pubmed-article:10617128pubmed:meshHeadingpubmed-meshheading:10617128...lld:pubmed
pubmed-article:10617128pubmed:meshHeadingpubmed-meshheading:10617128...lld:pubmed
pubmed-article:10617128pubmed:meshHeadingpubmed-meshheading:10617128...lld:pubmed
pubmed-article:10617128pubmed:meshHeadingpubmed-meshheading:10617128...lld:pubmed
pubmed-article:10617128pubmed:meshHeadingpubmed-meshheading:10617128...lld:pubmed
pubmed-article:10617128pubmed:meshHeadingpubmed-meshheading:10617128...lld:pubmed
pubmed-article:10617128pubmed:year2000lld:pubmed
pubmed-article:10617128pubmed:articleTitleReserpine pretreatment prevents increases in extracellular striatal dopamine following L-DOPA administration in rats with nigrostriatal denervation.lld:pubmed
pubmed-article:10617128pubmed:affiliationThird Department of Medicine, Hirosaki University School of Medicine, Japan. kkanhki@umin.ac.jplld:pubmed
pubmed-article:10617128pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10617128lld:pubmed